MVRIX Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$5.73M
- Investors
-
9
MVRIX General Information
Description
Operator of a biotechnology company intended for biologics discovery and development. The company develops new drugs based on platform technology related to membranes and viruses, enabling humans to be free from the attack of viruses and microorganisms.
Contact Information
Website
www.mvrix.co.krCorporate Office
- Room 513, Building 1, Ace Hitech City Pyeongchon
- 457-27, Heungan-daero, Dongan-gu, Anyang-si
- Hwaseong, Gyeonggi-do
- South Korea
Corporate Office
- Room 513, Building 1, Ace Hitech City Pyeongchon
- 457-27, Heungan-daero, Dongan-gu, Anyang-si
- Hwaseong, Gyeonggi-do
- South Korea
MVRIX Timeline
MVRIX Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 04-Sep-2026 | $5.73M | Completed | Clinical Trials - General | ||
| 2. Early Stage VC (Series A) | 13-Mar-2025 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | $2.41M | $2.41M | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
MVRIX Patents
MVRIX Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026212425-A1 | Lipid nanoparticles conjugated with clusterin-fused antibody | Pending | 31-Mar-2025 | ||
| WO-2026160580-A1 | Recombinant botulinum toxin and pharmaceutical composition containing same | Pending | 23-Jan-2025 | ||
| WO-2026010379-A1 | Pharmaceutical composition containing her2-binding lipid nanoparticles loaded with mrna encoding p53 protein | Pending | 02-Jul-2024 | ||
| WO-2026010380-A1 | Pharmaceutical lipid nanoparticle composition with improved targeted delivery ability and safety | Pending | 02-Jul-2024 | ||
| EP-4711379-A1 | Method for producing botulinum neurotoxin using soluble partner and gp41.1 intein | Pending | 07-Mar-2024 | C12N9/52 |
MVRIX Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ajin Industrial | Corporation | Minority | ||
| Interbest | Corporation | Minority | ||
| InterVest | Venture Capital | Minority | ||
| Korea Investment Partners | Venture Capital | Minority | ||
| Korea Omega Investment | Venture Capital | Minority |
MVRIX FAQs
-
When was MVRIX founded?
MVRIX was founded in 2021.
-
Where is MVRIX headquartered?
MVRIX is headquartered in Hwaseong, South Korea.
-
What industry is MVRIX in?
MVRIX’s primary industry is Biotechnology.
-
Is MVRIX a private or public company?
MVRIX is a Private company.
-
What is MVRIX’s current revenue?
The current revenue for MVRIX is .
-
How much funding has MVRIX raised over time?
MVRIX has raised $11.6M.
-
Who are MVRIX’s investors?
Ajin Industrial, Interbest, InterVest, Korea Investment Partners, and Korea Omega Investment are 5 of 9 investors who have invested in MVRIX.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process